What is the main difference between GHRP-6 and Ipamorelin?

Both GHRP-6 and Ipamorelin are researched in the context of hormonal, both with Moderate evidence strength.

Which has more clinical evidence, GHRP-6 or Ipamorelin?

GHRP-6 has 45 sources (12 human studies), rated Moderate evidence. Ipamorelin has 18 sources (4 human studies), rated Moderate evidence.

Are GHRP-6 and Ipamorelin FDA approved?

Neither GHRP-6 nor Ipamorelin is FDA-approved. Both remain research compounds without regulatory approval for clinical use.

Can GHRP-6 and Ipamorelin be used together?

There is no published clinical data on the safety or efficacy of using GHRP-6 and Ipamorelin together. Without controlled human studies evaluating this combination, the safety profile is unknown. Consult a qualified healthcare provider before considering any peptide regimen.

GHRP-6 vs Ipamorelin: Which Has Better Evidence?

Overview

Both GHRP-6 and ipamorelin stimulate GH release through the ghrelin receptor, but ipamorelin was designed for greater selectivity.

Selectivity Comparison

Effect	GHRP-6	Ipamorelin
GH Release	Strong	Strong
Cortisol	Increased	Minimal
Prolactin	Increased	Minimal
Appetite	Strong increase	Less effect

Why Selectivity Matters

GHRP-6’s effects on cortisol and prolactin may:

Be undesirable for many users
Limit long-term use potential
Cause unwanted side effects

Regulatory Status

Aspect	GHRP-6	Ipamorelin
FDA Status	Not approved	Not approved
Development	Research tool	Discontinued
WADA	Prohibited	Prohibited

Evidence Quality

Both have low evidence quality, but ipamorelin has slightly more human pharmacology data from Phase 1/2 studies.

Summary

Ipamorelin: More selective, fewer off-target effects
GHRP-6: Less selective, stronger appetite stimulation
Neither is approved for any indication

This comparison is for educational purposes only. Neither peptide is FDA-approved.

GHRP-6 vs Ipamorelin

GHRP-6

Ipamorelin